Try Alerts Free   |   Login
Health Care › Biological Products (No Diagnostic Substances)

TTNP Price Correlated With Financials For Titan Pharmaceuticals

Free historical financial statements for Titan Pharmaceuticals Inc. See how revenue, income, cash flow, and balance sheet financials have changed over 42 quarters since 2012. Compare with TTNP stock chart to see long term trends.

TTNP Stock Compared to Quarterly

TTNP Income Statement

Revenue, Net:150000
Revenue Per Share:0.0103
Cost of Goods & Services Sold:0
Selling, General & Admin Expense:1618000
Research & Development Expense:974000
Total Operating Expenses:2592000
Operating Income:-2442000
Net Income:-2462000
Earnings Per Share, Basic:-0.18
Shares Outstanding, Basic Avg:14629217

TTNP Cash Flow

Operating Activities Net Income:
Depreciation, Depletion & Amortization:51000
Change in Accounts Receiveable:-117000
Net Cash from Operations:-1767000
Net Cash from Operations Per Share:-0.1208
Net Cash from Financing Activities:3000
Property, Plant & Equipment Purchases:null
Net Cash from Investing Activities:null
Net Change in Cash & Equivalents:-1764000

TTNP Balance Sheet

Cash and Cash Equivalents:6585000
Accounts Receivable, Net:101000
Inventories:469000
Total Current Assets:7713000
Property, Plant & Equipment, Net:317000
Total Assets:8319000
Accounts Payable:443000
Current Portion of Long-Term Debt:null
Total Short-Term Liabilities:2524000
Long Term Debt, Non-Current Portion:null
Total Liabilities:2652000

Insider Trading

 
Change
Value
Transaction
SEC Form 4
Lazar David E.   10% Owner
1,910,269 sh at $1
$1,640,891
Buy

Major Holders (from 13F filings)

Investment Type
Change
Value (x$1000)
increase or decrease
Vanguard Group Inc
206,428 sh
 
$197
Group One Trading, L.P.
58,904 sh
14,147 sh
32%
$56
$10
Geode Capital Management, LLC
53,053 sh
 
$50
Renaissance Technologies LLC
36,510 sh
17,000 sh
87%
$35
$15
Tower Research Capital LLC (Trc)
10,041 sh
9,936 sh
9463%
$10
UBS Group Ag
7,123 sh
3,325 sh
88%
$7
$3
Level Financial Advisors, Inc.
987 sh
 
$1
Simplex Trading, LLC
354 sh
-3,452 sh
-91%
$0
-$3
Blackrock Inc.
60 sh
 
$0
Morgan Stanley
16 sh
 
$0
Advisor Group Holdings, Inc.
14 sh
-1 sh
-7%
$0
Rockefeller Capital Management L.P.
5 sh
 
$0
Westside Investment Management, Inc.
4 sh
 
$0
Newbridge Financial Services Group, Inc.
2 sh
 
$0
Joseph P. Lucia & Associates, LLC
2 sh
2 sh
NEW
$0
FMR LLC
1 sh
 
$0
Winning Points Advisors, LLC
0 sh
-11,685 sh
-100%
$0
-$15
Widmann Financial Services, Inc.
0 sh
-1 sh
-100%
$0
Proequities, Inc.
0 sh
 
$0
COMPANY PROFILE
1.     Organization and Summary of Significant Accounting Policies The Company We are a pharmaceutical company developing therapeutics utilizing our proprietary long-term drug delivery platform, ProNeura ®, for the treatment of select chronic diseases for which steady state delivery of a drug has the potential to provide an efficacy and/or safety benefit. ProNeura consists of a small, solid implant made from a mixture of ethylene-vinyl acetate, or EVA, and a drug substance. The resulting product is a solid matrix that is designed to be administered subdermally in a brief, outpatient procedure and is removed in a similar manner at the end of the treatment period. These procedures may be performed by trained health care providers, or HCPs, including licensed and surgically qualified physicians, nurse practitioners, and physician’s assistants in a HCP’s office or other clinical setting. Our first product based on our ProNeura technology was Probuphine ® (buprenorphine implant), which is approved in the United States, Canada and the European Union, or EU, for the maintenance treatment of opioid use disorder in clinically stable patients taking 8 mg or less a day of oral buprenorphine. While Probuphine continues to be commercialized in Canada and in the EU (as Sixmo™) by other companies that have either licensed or acquired the rights from Titan, we discontinued commercialization of the product in the U.S. during the fourth quarter of 2020. Discontinuation of our commercial operations has allowed us to focus our limited resources on important product development programs and transition back to a product development company. In November 2020, pursuant to prior stockholder authorization, our board of directors, or the Board, effected a reverse split of the outstanding shares of our common stock at a ratio of one share for every thirty shares then outstanding, or the Reverse Split. Pursuant to their respective terms, the number of shares underlying our outstanding options and warrants was reduced and their respective exercise prices increased by the Reverse Split ratio. The number of shares of common stock authorized and the par value of $0.001 per share did not change as a result of the Reverse Split. All share and per share amounts contained in this Annual Report on Form 10-K give retroactive effect to the Reverse Split. The accompanying financial statements have been prepared assuming we will continue as a going concern. At December 31, 2021, we had cash and cash equivalents of approximately $6.0 million, which we believe, together with the net cash proceeds of approximately $5.0 million received from the February 2022 Offering, is sufficient to fund our planned operations to the end of the third quarter of 2022. We will require additional funds to finance our operations. We are exploring several financing alternatives; however, there can be no assurance that our efforts to obtain the funding required to continue our operations will be successful. There is substantial doubt about our ability to continue as a going concern. Discontinued Operations In October 2020, we announced our decision to discontinue selling Probuphine in the U.S. and wind down our commercialization activities, and to pursue a plan that will enable us to focus on our current, early-stage ProNeura-based product development programs. The accompanying financial statements have been recast for all periods presented to reflect the assets, liabilities, revenue and expenses related to our U.S. commercialization activities as discontinued operations (see Note 11). The accompanying financial statements are generally presented in conformity with our historical format. We believe this format provides comparability with the previously filed financial statements. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the amounts reported

Data imported from Titan Pharmaceuticals Inc SEC filings. Check original filings before making any investment decision.